Back

Frequency, management and outcomes of patients with stable coronary artery disease eligible for COMPASS. An analysis of the CLARIFY registry.

2 September 2019 (11:54 - 12:12)
Organised by:
Congress Presentation Part of: Antithrombotic therapy for coronary artery disease: opportunities and challenges Epidemiology, Prognosis, Outcome ESC Premium Access ESC Congress 2019

About the speaker

Photo
Doctor Emmanuel Sorbets

Hospital Hotel-Dieu, Paris (France)

3 More presentations in this session

Presentation thumbnail
State of the Art - New options in antithrombotic therapy for coronary artery disease
Professor K. Newby (Durham, US)
Slides Video
Presentation thumbnail
Atherothrombotic risk and outcomes following guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome:a post-hoc analysis of the TROPICAL-ACS trial
Assistant Professor K. Rizas (Munich, DE)
Abstract Slides Video
Presentation thumbnail
Secondary prevention in 2030: will antiplatelets or anticoagulants prevail?
Professor D. Angiolillo (Jacksonville, US)
Slides Video

Access the full session

Session thumbnail
Antithrombotic therapy for coronary artery disease: opportunities and challenges

The Event

Event poster

ESC Congress 2019

2 September 2019 11:54 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources